These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10491729)

  • 1. Galenic development and pharmacokinetic profile of indapamide sustained release 1.5 mg.
    Damien G; Huet de Barochez B; Schiavi P
    Clin Pharmacokinet; 1999; 37 Suppl 1():13-9. PubMed ID: 10491729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers.
    Schiavi P; Jochemsen R; Guez D
    Fundam Clin Pharmacol; 2000; 14(2):139-46. PubMed ID: 10796061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical positioning of indapamide sustained release 1.5mg in management protocols for hypertension.
    Leonetti G
    Drugs; 2000; 59 Suppl 2():27-38; discussion 39-40. PubMed ID: 10678595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indapamide sustained release: a review of its use in the treatment of hypertension.
    Robinson DM; Wellington K
    Drugs; 2006; 66(2):257-71. PubMed ID: 16451099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of indapamide sustained release 1.5 mg in hypertension.
    Donnelly R
    Clin Pharmacokinet; 1999; 37 Suppl 1():21-32. PubMed ID: 10491730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the pharmacology and clinical efficacy of indapamide sustained release.
    Sassard J; Bataillard A; McIntyre H
    Fundam Clin Pharmacol; 2005 Dec; 19(6):637-45. PubMed ID: 16313275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic benefit of a low dose of indapamide: results of a double-blind against placebo European controlled study].
    Asmar R; Guez D; Malbezin M; Brault Y; de Cordoue A; Barrandon S; Bruxelles MC; Chastang C
    Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1083-7. PubMed ID: 8572850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hypertension with indapamide 1.5 mg sustained-release form: synthesis of results].
    Guez D; Mallion JM; Degaute JP; Malini PL; Baldwin R; Rodriguez-Pujol D; de Cordoüe A; Barrandon S; Chastang C; Safar M
    Arch Mal Coeur Vaiss; 1996 Sep; 89 Spec No 4():17-25. PubMed ID: 8952810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renaissance of diuretics in the treatment of hypertension].
    Hörl WH
    Wien Klin Wochenschr; 1999 Nov; 111(21):903-7. PubMed ID: 10599155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Pharmacokinetics and Bioavailability of Fixed-Dose Combination Tablet and Monotherapy Combination of Allisartan Isoproxil and Indapamide Sustained-Release in Healthy Chinese Volunteers.
    Fan N; Gongmin Z; Wenming C; Jiao Y; Ruijie Z; Yan C; Xiangming T; Yi W
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):190-196. PubMed ID: 37691309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of indapamide 1.5 mg sustained release coated tablets in the therapy of arterial hypertension].
    Asmar R
    Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):94-104. PubMed ID: 9772936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and pharmacokinetic profile of a newly-developed twice-a-day sustained-release paracetamol formulation.
    Liu DJ; Collaku A; Youngberg SP
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):172-81. PubMed ID: 25500485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concluding remarks. Pursuit of the optimal outcome in hypertension.
    Hansson L
    Clin Pharmacokinet; 1999; 37 Suppl 1():33-8. PubMed ID: 10491731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation, Characterization and in vivo Evaluation of Simple Monolithic Ethylcellulose-coated Pellets Containing Topiramate with Biphasic Release Characteristics.
    Gong W; Wang Y; Shao S; Xie S; Shan L; Yang M; Gao C; Zhong W
    Curr Drug Deliv; 2016; 13(2):245-54. PubMed ID: 26563941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and experimental design of a novel controlled-release matrix tablet formulation for indapamide hemihydrate.
    Antovska P; Ugarkovic S; Petruševski G; Stefanova B; Manchevska B; Petkovska R; Makreski P
    Pharm Dev Technol; 2017 Nov; 22(7):851-859. PubMed ID: 26402027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic evaluation of a sustained-release formulation of trihexyphenidyl in healthy volunteers.
    Cheung WK; Stravinski SS; Engel SI; Sia LL; Yacobi A; Silber BM
    J Pharm Sci; 1988 Sep; 77(9):748-50. PubMed ID: 3225767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Drug-Drug Interaction of Allisartan Isoproxil and Indapamide Sustained-Release Formulation.
    Yi W; Lin S; Hao R; Shao Y; Wang Y; Yu J; Fang L; Zhu J; Wang A; Wu Y; Huang H; Deng C; Sun J; Zhao H; Wang Y; Tong X
    Clin Pharmacol Drug Dev; 2023 Nov; 12(11):1051-1059. PubMed ID: 37814929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of the pharmacokinetics of a sustained-release formulation of a tramadol/acetaminophen combination in healthy subjects.
    Im YJ; Jeon JY; Kim EY; Kim Y; Oh DJ; Yoo JS; Shin DH; Chae SW; Kim MG
    Clin Ther; 2015 Feb; 37(2):376-89. PubMed ID: 25618318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies.
    Weidmann P
    Drug Saf; 2001; 24(15):1155-65. PubMed ID: 11772148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.